Deals this week: Tear Film Innovations, ReShape Lifesciences, Nissha

25 May 2018 (Last Updated November 22nd, 2018 11:29)

Tear Film Innovations Inc has raised $8.5m through a series B venture financing round led by Visionary Ventures Fund LLC and Bluestem Capital Company LLC.

Tear Film Innovations Inc has raised $8.5m through a series B venture financing round led by Visionary Ventures Fund LLC and Bluestem Capital Company LLC.

Based in the US, Tear Film Innovations is a designer and producer of breakthrough products for the treatment of evaporative dry eye and related syndromes, including meibomian gland dysfunction (MGD).

The company plans to use the funds towards the development of its iLux evaporative dry eye system for the treatment of blocked meibomian glands in the eyelids.

ReShape Lifesciences Inc plans to raise $125m through a public offering of shares of its common stock, preferred stock, and securities warrants.

The funds are intended to be used towards working capital, clinical development activities, and other general corporate purposes.

Based in the US, ReShape Lifesciences is a developer of minimally invasive medical devices.

Fox Rothschild LLP was appointed as the legal advisor for the offering.

Nissha Co Ltd’s subsidiary Graphic Controls Group has purchased the medical technologies business division of HeartSync Inc.

Based in Japan, Nissha is a developer of industrial materials and other medical devices, while Heart Sync is a US-based designer and developer of disposable electrodes for cardiac resuscitation and pacing.

“ElectroCore Inc has filed a registration statement with the US Securities and Exchange Commission for an initial public offering (IPO) of shares to raise $74.75m.”

The acquisition complements Graphic Controls Group’s medical technologies business.

AorTech International Plc has raised £0.5m ($0.67m) in an open offering of 150,000 shares priced at £0.3 ($0.4) a share.

AorTech has simultaneously raised £1.7m ($2.29m) through a private placement of 5.7 million shares priced at £0.3 ($0.4) a share. The company has also raised £0.4m ($0.54m) through the private placement of 1.26 million shares priced at £0.3 ($0.4) a share.

AorTech plans to use the funds towards the development of textile substrate products and for general working capital purposes.

Based in the UK, AorTech is a medical technology company focused on the commercialisation of biomedical polymer technology, components and medical devices.

Becton Dickinson and Co plans to raise €30m ($354.36m) through a public offering of 1.401% notes due 2023.

Bection also simultaneously announced plans to raise £250m ($337.37m) through a public offering of 3.02% notes due 2025.

The company will use the cash towards the redemption of outstanding notes and to repay its debts.

Based in the US, Becton Dickinson is a medical technology company that manufactures and sells medical devices, instrument systems, and reagents.

BiVacor Pty Ltd has raised funds through a venture financing round provided by OneVentures Healthcare Fund III.

Based in Australia, BiVacor is a medical technology company focused on the development of the artificial heart.

The company plans to develop its external Total Artificial Heart (TAH) controller.

ElectroCore Inc has filed a registration statement with the US Securities and Exchange Commission for an initial public offering (IPO) of shares to raise $74.75m.

ElectroCore will grant the underwriters a 30-day option to purchase additional shares of common stock.

Based in the US, ElectroCore is a neuroscience and technology company focused on the development of non-invasive vagus nerve stimulation therapy for the treatment of multiple conditions in neurology.

The company plans to use the funds to hire business managers and expand marketing programmes. The funds are also intended to be used towards working capital and other general corporate purposes.